20 September 2024 - The FDA’s priority review voucher program for rare paediatric diseases is set to lapse on 30 September without congressional intervention. 

And while advocates and analysts expect lawmakers to reauthorise the program, the timing is unclear as House leaders struggle to pass a stopgap spending measure to avert a Government shutdown on the same day.

Read Politico article